Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses

BMC Microbiology

Research Article

Miao Zhao¹  Yi Zeng¹  Yu Bai¹  Wang Sheng¹  Wei Liu¹  Xiangqian Xiao¹  Paul KS Chan²  Yuming Huang³  Shan Cen⁴  Xin Sun⁵ 

[1] College of Life Science and Bioengineering, Beijing University of Technology, 100, Pingleyuan, 100124, Chaoyang District, Beijing, PR China;Department of Microbiology, Chinese University of Hong Kong, Hong Kong, PR China;Department of Neurology, Beijing Ditan Hospital, Capital Medical University, Beijing, PR China;Department of Virology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, PR China;Research Center for Life Science, Beihua University, 3999, Binjiangdong Road, 132013, Jinlin, Jilin Province, PR China;

关键词: Enterovirus 71;    Vaccine;    VP4;    Peptide;    Chimeric virus-like particle;   

DOI  :  10.1186/1471-2180-13-287

 received in 2013-09-20, accepted in 2013-12-02,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundEnterovirus 71 (EV71) is major cause of hand, foot and mouth disease. Large epidemics of EV71 infection have been recently reported in the Asian-Pacific region. Currently, no vaccine is available to prevent EV71 infection.ResultsThe peptide (VP4N20) consisting of the first 20 amino acids at the N-terminal of VP4 of EV71 genotype C4 were fused to hepatitis B core (HBcAg) protein. Expression of fusion proteins in E. coli resulted in the formation of chimeric virus-like particles (VLPs). Mice immunized with the chimeric VLPs elicited anti-VP4N20 antibody response. In vitro microneutralization experiments showed that anti-chimeric VLPs sera were able to neutralize not only EV71 of genotype C4 but also EV71 of genotype A. Neonatal mice model confirmed the neutralizing ability of anti-chimeric VLPs sera. Eiptope mapping led to the identification of a “core sequence” responsible for antibody recognition within the peptide.ConclusionsImmunization of chimeric VLPs is able to elicit antibodies displaying a broad neutralizing activity against different genotypes of EV71 in vitro. The “core sequence” of EV71-VP4 is highly conserved across EV71 genotypes. The chimeric VLPs have a great potential to be a novel vaccine candidate with a broad cross-protection against different EV71 genotypes.

【 授权许可】

Unknown   
© Zhao et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.